Replies to post #131904 on Biotech Values

[iwfal]

Rather, substitutable FoB’s also have an opportunity to claim a portion of the addressable market for non-substitutable FoB’s (which I estimated at 35-40% of the pie

Proviso: To take advantage of the above, development programs for substitutable FoB have to be started early—i.e. they have to be well into the research phase even now.

I would assume that subs genetics will inherently be 2 or 3 yrs behind non-subs biosims. So biosims will have already gotten most of what they ever would get. And then, in agreement with you proviso, it would be very difficult for a subs generic to grab back market from the biosims.